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Abstract.  
The Gd(III) complexes currently used as MRI contrast agents are hydrophilic agents that distribute 
in the vascular and extracellular compartments. The visualization of atherosclerotic plaques 
requires systems endowed with lipophilic characteristics. Several Gd(III) complexes bearing 
lipophilic substituents have been reported. Among them Gd(III) complexes containing one or two 
aliphatic chains appears particularly useful for the intended application. These amphiphilic Gd(III) 
complexes have been incorporated into various type of supramolecular adducts that ensure 
enough sensibility for their detection in MR images of atherosclerotic plaques. Much attention has 
been devoted to the use of HDL and LDL Gd-loaded particles. The presence of long aliphatic 
chain(s) promotes the spontaneous aggregation of these complexes to form micelles that may 
associate as such to the surface of HDL particles. It has been shown that the transfer of single 
amphiphilic complexes into the lipidic core of the particles is possible by de-assembling the 
micelles through the formation of “host-guest” adducts with cyclodextrin. Gd-loaded liposomes 
have also been successfully tested in plaque detection as well as perfluoronanoparticles loaded 
with CEST agents. 
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Introduction.  
The hallmarks of vulnerable atherosclerotic plaques are the presence of a high number of 
infiammatory cells and of a heterogeneous composition with high variability even within the same 
individual. [1] In the last decade an intense research activity, aimed at exploiting non-invasive 
clinically available imaging, has increased in order to detect and characterize the atherothrombotic 
disease in its various stages and at different anatomical sites. Magnetic Resonance Imaging (MRI) 
is a promising technique to study cardiovascular diseases “in vivo”. In fact, although its sensitivity 
is lower in comparison to nuclear and optical modalities, the high spatial resolution (<100um) of 1H-
MRI provides detailed morphological and functional informations, and the absence of radiation 
makes it safer than techniques based on the use of radioisotopes.[2] MRI contrast is the result of a 
complex interplay that combines instrumental parameters and longitudinal (T1) and transverse (T2) 
water proton relaxation times. In both clinical and experimental settings it is customary to alter the 
endogenous contrast by the use of contrast agents (CAs) that decrease the longitudinal and 
transverse relaxation time of water protons in the tissues were they distribute.[3] Most of CAs used 
in clinical settings are polyaminocarboxylate complexes of Gd3+ ion that contains seven unpaired 
electrons. The ligands are multidentate (seven or eight donor atoms) in order to form complexes 
with very high thermodynamic and kinetic stability thus limiting the “in vivo” release of the toxic free 
metal ion. In a 1H MR image, there is a direct proportionality between the observed relaxation 
enhancement and the concentration of the paramagnetic MRI reporter. However, MRI suffers from 
an intrinsic insensitivity with respect to the competing imaging modalities. This drawback has to be 
overcome by designing suitable amplification procedures unusually based on the accumulation of 
the imaging agents at the targeting sites.[4] A general strategy for achieving this goal utilizes nano-
sized systems such as liposome, micelles, microemulsions, polymers etc…that are able to deliver 
a huge payload of Gd complexes[5-6]. The nanocarriers may be functionalized with suitable 
vectors that provide the overall particles with the required recognition capabilities towards the 
selected target. A straightforward extension of this approach has involved the exploitation of 
naturally occurring nanosized aggregates such as the different types of lipoproteins (HDL, LDL) [7] 
that enter the atherosclerotic plaque without the need of further functionalization with specific 
vectors.  
Currently, there are no clinically established methods to non-invasively differentiate between stable 
and vulnerable plaques and to identify rupture prone plaques. Therefore, there are many activities 
devoted to the development of Molecular Imaging protocols able to visualize, in real time, the 
expression of specific receptors, enzymes, inflammation cell activity (macrophages, neutrophils, 
and lymphocytes), and neovascularisation in order to find useful markers of plaque instability. In 
this review, the use of both natural and synthetic lipid based nanoparticles as vectors for a high 
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payload of contrast agents units to the atherosclerotic plaques is surveyed and their diagnostic 
prediction ability is discussed.  
High Density Lipoproteins. (HDL)  
HDLs are endogenous nanoparticles with a diameter of 7–13 nm that accumulate at 
atherosclerotics plaques. They are composed of cholesterol, phospholipids (phosphatidylcholines 
are particularly abundant) [8] and apolipoproteins. The major apolipoprotein of HDL is apoA-I, 
(although other apolipoproteins may also be present) which is responsible for scaffolding the size 
and shape of natural HDL particles. Several characteristics of HDLs make these systems highly 
attractive for molecular delivery: namely i) the amphiphilic nature of HDLs allows their loading with 
hydrophobic and amphiphilic small molecules, drugs, and proteins; ii) HDLs, being endogenous 
structures, are biocompatible; iii) cell surface receptors for HDL are very active and offer the 
potential for targeted drug delivery to cells that express them.[9] Three routes to prepare Gd-based 
MRI HDL particles have been explored, and they are based on: i) native HDL; ii) reconstituted 
HDL; ii) synthetic HDL, respectively. All of them rely on the use of amphiphilic Gd-complexes and 
several structural types have been proposed. Due to the toxicity issues associated with free Gd 
ions, it is crucial that chelators bind Gd3+ ions with high thermodynamic stability. This requirement 
is particularly stringent in molecular imaging protocols where Gd containing probes own prolonged 
circulation life times[10]. In fact, it has been shown that Gd complexes with thermodynamic 
association constants  1017 when added to cell incubation media, show net transfer of Gd ions to 
the cell membrane followed by a slower internalization process.[11]. Figure 1 shows two types of 
amphiphilic Gd-complexes used to prepare Gd-loaded HDL particles. They contain one or two C14 
or C16 aliphatic chains that allow their incorporation. into HDL particles. 
Diethylenetriaminepentaacetic distearylamide (DTPA-SA) and 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine diethylenetriamine pentacetic acid (DTPA-DMPE) with eight coordinating 
atoms leaving one site available to coordinate a water molecule whereas AAZTA ligand has only 
seven coordinating atoms thus allowing the coordination of two water molecules.[12] As a 
consequence, Gd-AAZTA-C17-labeled HDL particles have a four times higher longitudinal 
relaxivity (the key parameter of MRI contrast-generating potential), making these systems very 
efficient contrast agents[13]. Once dissolved in water, these amphiphilic Gd-complexes form stable 
micelles with different critical micellar concentrations (CMC). In fact, Gd-DTPA derivatives, that are 
functionalized with two aliphatic chains, show a cmc<0.05 mM whereas Gd-AAZTA-C17 has a 
CMC = 0.1 mM.[14] Briley-szabo and coworkers [13] showed that the successful incorporation of 
the Gd-complexes into native HDL is strongly dependent upon the CMC of the used amphiphile. At 
concentrations below the CMC the amphiphilic Gd(III)-complexes are easily integrated into the 
lipoproteins and stable HDL adducts with high stability constants are formed. At Gd-complexes 
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concentrations above the CMC, larger particles are formed. These particles display a relaxivity 
higher than that of the particles obtained with some amphiphilic Gd complexes below the cmc. The 
larger size implies that the particles tumble more slowly, yielding an increased relaxivity. The 
reason for the formation of larger sized HDL particles is not well elucidated, but it may be due to 
the formation of fused HDL species as suggested by Pownall (15). In these studies exposure of 
HDL to cholate above the CMC values results in the loss of ApoA-I and phospholipid from the 
lipoprotein surface. This structural change causes the exposure of the neutral lipid core to the 
surrounding aqueous phase thereby inducing the fusion of two or more ApoA-I/phospholipid-
depleted HDL particles, as depicted in Figure 2. In order to avoid the formation of these large 
adducts it is possible to deassemble the Gd-complex containing micelles in aqueous solution by 
adding an excess of -cyclodextrin (-CD). In fact, -CD yields a molecular dispersion of the 
amphiphilic complexes, as a consequence of the formation of supramolecular “host-guest” adducts 
because the lipophilic chains have a very good affinity for the hydrophobic cavity of -CD (Figure 
3). Upon the addition of HDL, an equilibrium between the monomeric Gd-complex/-CD adducts 
and Gd-complex/HDL particle is established. Since the stability of Gd-complex/HDL particle is 
higher, the equilibrium is shifted toward the formation of the latter adducts. By using this method an 
efficient HDL contrast agent containing up to 80 Gd-complex units has been prepared. An 
alternative approach relies on the use of HDL reconstituted with phospholipids and contrast 
agents, with or without cholesterol. The procedure consists of delipidation (by standard methods) 
of HDL particles to yield apo-HDL proteins, mainly apo-A-I. Using this method, Frias and coworkers 
[16] incorporated the phospholipid-based contrast agent, Gd-DTPA-DMPE into the reconstituted 
particle. The size of the resulting particles was approximately 9 nm diameter and each particle 
contained between 15 and 20 molecules of Gd-DTPA-DMPE. They targeted atherosclerotic 
plaques and observed an enhancement of the MRI signal that wss related to the plaque 
macrophage content. This basic platform structure was then modified in order to improve the 
uptake by macrophages in the atherotic tissue by incorporating the Apo-E derived peptide (P2A2) 
into the phospholipid layer. This peptide was derived from the LDL-receptor-binding domain of 
ApoE, and it has been shown to facilitate cellular uptake of nanoparticles [17]. The uptake of these 
P2A2 containing HDL was measured in J774A.1 macrophages in vitro, using fluorescence 
measurements and MRI and compared with the traditionally reconstituted HDL. The new 
formulation produced greater contrast than the original HDL formulation also in the MRI images of 
aortas of ApoE−/− mice, indicating that the P2A2 peptide maintains the same enhanced effect in 
vivo. A new artificial HDL-based platform, labeled with MRI and Optical agents, has been recently 
developed using synthetic peptides (37pA) instead of natural ApoA-I[18]. This approach could have 
the advantage of avoiding the use of plasma derived products and must be more suitable for a 
clinical translation. These synthetic HDL-based contrast agents were synthesized via hydration of a 
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mixed phospholipids film with a solution of 37pA followed by sonication, filtration and 
concentration. Some of these phospholipids were gadolinium labeled or fluorophore labeled. 37pA-
HDL was tested as an atherosclerosis-specific contrast agent in ApoE−/− mice on a 9.4 T small-
animal scanner. At 24 h post injection the signal intensity in the aorta of the ApoE−/− mice 
increased by an average of 94%, as compared to pre-injection images.(Figure 4) When 37pA-HDL 
was tested in non-atherosclerotic, wild-type mice the increase in signal intensity in aortas region 
was not significant. This finding clearly demonstrates the specificity of 37pA-HDL for the 
visualization of atherosclerotic tissue. 
 
Low Density Lipoproteins (LDL).  
The low-density lipoproteins (LDLs) are another member of plasma lipoproteins family and 
represent the main biological carriers of unesterified and esterified cholesterol to extrahepatic 
tissues. The membrane associated protein ApoB100 mediates the recognition of LDLs receptors 
and the subsequent uptake into cells through receptor-mediated endocytosis [19]. Altered LDLR 
levels are found in a variety of pathological conditions (e.g., atherosclerosis) [20] and several 
tumors overexpress LDLRs to supply the high cholesterol demand of rapidly dividing cells [21]. In 
the literature there are many examples on the use of LDL as carriers for imaging agents to tumor 
cells (Table 1). As a consequence of their size (18-25 nm), LDL can incorporate a high number of 
MRI contrast agents (up to 400 probes per protein). The long reorientational time of the Gd-
complex incorporated in the supramolecular adduct yields higher relaxivities with respect the free 
complex in particular at relatively low magnetic field strengths (e.g.1 T). LDLs appear ideal for the 
delivery of drug and imaging agents since they are able to circulate in the bloodstream for a 
significant amount of time. Furthermore, LDLs are more efficient in terms of loading capacity (with 
respect the smaller HDL).  
Table 1. Types of imaging agents / LDL nanoformulations used in cancer diagnostic. 
 
Imaging 
Technique 
 
Imaging agent 
 
Tumor type 
 
Loading 
procedure 
Agent/LDL 
ratio 
(loading 
efficiency) 
 
Reference 
MRI Gd-DTPA-SA Hepg2 (human 
hepatocarcinoma) 
core 
loading 
200:1 [22] 
Confocal 
Microscopy 
meso to- 
meso ethyne-bridged 
tris[(porphinato)zinc(II)] 
B16 (murine 
melanoma) 
core 
loading 
30:1 [23] 
Cryo-imager 
(optical 
1,1_-dioctadecyl- 
3,3,3_,3_-
Hepg2 (human surface 34:1 [24] 
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imaging) tetramethylindotricarbocyanine 
iodide 
hepatocarcinoma) loading 
Two-Channel 
I&Q 
Spectrometer 
tetra-t-butyl silicon 
naphthalocyanine 
bisoleate 
Hepg2 core 
loading 
100:1 [25] 
CT 2-oleoylglycerol 1,3-
bis(iodopanoate 
Hepg2 core 
loading 
nd [26] 
Confocal 
Fluorescent 
Imaging 
hypericin U87-MG (Human 
Glioma) 
core 
loading 
100:1 [27] 
Confocal 
Microscopy 
dioleyl fluorescein, Human fibroblast core 
loading 
nd [28] 
MRI Gd-AAZTA-C17 B16, Hepg2 surface 
loading 
300:1 [29] 
MRI [N-(DOTAMA-
C6)carbamoylmethyl]C’-
palmitamidomethyl-ortho-
carborane 
B16, Hepg2, U87-
MG 
surface 
loading 
190:1 [30] 
 
In spite of these positive characteristics, Gd-loaded LDLs have been less used for the visualization 
of atherosclerotic lesions. In fact, it is well accepted that high serum levels of LDL play a main role 
in the initiation and progression of the pathology through LDL matrix interaction in the 
subendothelial space of an initiating plaque. Recently Yamakoshi and coworkers [31] reported on 
the preparation of LDL-based nanoparticles for MRI detection of atheroplaques in mice apoE_/_ or 
LDL_/_ models. LDL particles were loaded with GdDO3A-OA (Figure 5) which bears an oleic acid 
anchor to facilitate incorporation into the lipid layer of the particle. In vivo studies using 
atherosclerotic mouse models showed a significant Gd3+ retention in the atheroplaques by ICP/MS 
and good enhancement in MRI images. These results clearly demonstrate that LDL nanoparticles 
are a useful vehicle for delivering a high payload of imaging agents to atherosclerosis exploiting 
the natural affinity for plaque components of LDL-based particles. 
 
Liposomes. 
Liposomes are colloidal particles that are composed of either natural or synthetic amphiphilic lipids 
and have been proposed as carriers for both therapeutic and contrast agents to the atherosclerotic 
plaques as the payload can be encapsulated in their internal aqueous cavity and/or intercalated in 
the phospholipid bilayer, thus allowing the transport of both hydrophilic and hydrophobic 
compounds (figure 6). A specific class of liposomes, named “long time circulating” polyethylene 
glycol (PEG)–coated liposomes, is able to accumulate in solid tumors as a consequence of 
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increased microvascular permeability and defective lymphatic drainage [32]. Since, atherosclerotic 
lesions are often associated with increased membrane permeability, (PEG)–coated liposomes 
have been proposed to detect atherosclerosis/neointimal thickening [33], in ApoE-KO mouse 
model of atherosclerosis. Gd-DTPA-BSA has been used as MRI contrast agent intercalated in the 
phospholipid bilayer of these (PEG)-coated liposomes. No abnormalities were detectable with 
either non-enhanced imaging methods (T1-w, T2-w, and PD-w) or conventional Gd-DTPA contrast 
enhancement at the time points at which a strong signal enhancement was observed with 
paramagnetic liposomes. Thus, the use of the liposomal contrast agent considerably improved the 
detection of the pathology that was otherwise poorly visible by traditional MRI scanning. In order to 
target liposomes to specific markers of atherosclerosis it is possible to add to the phospholipid 
formulation a small % of a functionalized phospholipid. The targeting moiety is conjugated at the 
end of the PEG chain, and it may consists of peptides (or peptide analogues) containing the Arg–
Gly–Asp (RGD), phosphatidylserine (PS), folic acid, etc. In fact, it is well known that the RGD 
peptide sequence has high affinity for v3-integrin that is a key endothelial cell receptor over-
expressed by neo-formed vessels.[34] Its specificity and ubiquitous expression has made it a 
specific marker for the visualisation of vascular changes using nuclear or other imaging modalities. 
Alternatively, imaging strategies that pursue the visualization of inflammatory cells appear 
particularly attractive in view of the fundamental role of inflammation in atherosclerosis [35]. 
Macrophage targeting strategies are particularly attractive due to their ubiquitous presence and 
positive correlation with complications of atherosclerosis. It is known that exposed 
phosphatidylserine (PS) residues present in the outer surface of apoptotic cells promotes 
macrophage recognition by macrophage scavenger receptor/CD36 followed by rapid phagocytosis 
[36]. Accordingly, it has been hypothesized by Maiseyeu and co-workers [37] that mimicking 
apoptosis with liposomes containing PS may represent an attractive approach for molecular 
imaging of atherosclerosis. Liposomal composition can be easily modulated to include different 
lipids into the vesicle double layer as well as to entrap paramagnetic materials and fluorescence 
tags for in vivo monitoring of tissue/cell-specific delivery. In this approach, a simple route to 
prepare nonPEGylated liposomes containing the lipophilic Gd chelate-Gd-DTPA-SA and 
fluorescent organic dye Rhodamine B has been used to assess cellular uptake. PS liposomes 
appear to be avidly taken up by macrophages through a specific pathway for PS-containing 
epitopes, as these are analogous to exteriorized PS residues as a consequence of apoptosis. No 
significant decreases in T1 shortening was detected beyond 2% PS, while a continuing increase in 
fluorescent uptake of Gd-PS has been observed in “in vitro” studies at least to the 12% PS 
concentration. This is likely due to the intracellular localization of paramagnetic liposomes inside 
vesicles (endosomes and/or lisosomes) due to the internalization process based on receptor 
mediated endocytosis. In fact, the liposome intracellular distribution in vesicles can limit the 
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attainable relaxation enhancement as a consequence of the reduced water exchange across the 
barriers among the different compartments.[38-40]. On the contrary, changes in fluorescence 
measurements are typically linear over the ranges studied. 
Targeted Paracest Nanoparticles. 
Among MRI contrast agents, CEST (chemical exchange saturation transfer) agents have the 
unique property of yielding a so-called “frequency-encoded” contrast that may allow, analogous to 
optical imaging probes, the visualization of different agents in the same region.[41,42] The 
frequency-encoded MRI contrast generated by CEST agents is the result of the selective 
irradiation at the resonance frequency of the labile protons of the probe, whose exchange with the 
bulk water protons causes a decrease of their MRI signal. In such a way, a rather small 
concentration of mobile protons (e.g. in the millimolar range) may be detected in the MR image. 
The sensitivity of a CESTagent is primarily dependent on the number of NMR-equivalent mobile 
protons that operate the saturation transfer (ST) to the bulk water resonance. One method of 
increasing the sensitivity of PARACEST agents is to incorporate multiple metal chelates into a 
macromolecular scaffold such us perfluoronanoparticles.(PFC) Cai and coworkers [43] explored 
the use of PARACEST loaded with PFC nanoparticles by coupling 19F-MRI quantification and a 
mathematical modeling of the PARACEST signal. The particles were targeted to fibrin that is an 
abundant component of thrombi and an early marker of ruptured atherosclerotic plaques. 
Identification of fibrin could help detect ruptured plaques and direct therapeutic interventions to 
prevent or improve the consequences of a heart attack or stroke. 
Concluding Remarks. 
The herein surveyed results show that amphiphilic Gd complexes can be loaded on lipoproteins 
yielding highly sensitive MRI reporters. The targeting properties of HDL and LDL appear not to be 
significantly affected by the Gd-payload thus making these systems efficient agents for plaque 
visualization. The clinical translation of these interesting results will rely, first al all, on the design of 
biodegradable Gd-containing amphiphilic complexes. In fact, amphiphilic molecules like the Gd-
complexes functionalized with the long aliphatic chains reported in this survey, are expected to 
have good affinity for membrane phospholipid components as well as for several transporting 
proteins. Ultimately, they are expected to accumulate in liver and spleen. In principle their 
transformation into biodegradable molecules can be tackled by introducing an hydrolizable linkage 
between the lipophilic moiety and the Gd(III) complex. Obviously, the design of the agents has to 
avoid that the release of the Gd containing complex occurs only after the targeting step. Finally, 
one may foresee a larger involvement of the emerging class of CEST agents in atherosclerosis 
MRI diagnosis. These agents allows multiple epitope detection in the same MR image, a task that 
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appears highly relevant to the characterization of vulnerable plaques  as their instability is the 
result of several concomitant factors whose simultaneous assessment is clearly most in need.  
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Figure legends. 
Figure 1. Schematic representation of Gd-DTPA-DMPE and Gd-AAZTA-C17. 
Figure 2. Schematic depiction of the fusion of two or more ApoA-I/phospholipid-depleted 
HDL particles as a consequence of the interaction with amphiphilic Gd(III)-complexes 
micelles. 
Figure 3. Formation of the supramolecular “host-guest” adducts formed by amphiphilic 
Gd(III)-complexes and -cyclodextrin. 
Figure 4. Representative MR images of the aorta of apoE-KO mice pre- and 24 hours 
post-injection with 18A-Gd (left panels) and 37pA-Gd (right panels). Figure adapted with 
permission from Cormode DP et al. Bioconjug Chem. 2009; 20(5):937-43. Copyright 2009 
American Chemical Society. 
Figure 5. Schematic representation of the Gd(III)DO3A-OA complex. 
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Figure 6. Schematic depiction of a stealth liposome loaded with both amphiphilic and 
hydrophilic Gd(III)  -complexes. 
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